Order-driven interest in Aehr Test Systems

Aehr Test Systems (AEHR) is back on investors’ radar after securing a US$14 million order for its FOX-XP wafer-level test systems from a leading AI processor customer, tying the story closely to data center hardware demand.

At a share price of US$35.67, the stock has recently pulled back 5.26% on a 1 day share price return, but that comes after a 23.68% 1 month share price return and a very large 1 year total shareholder return. This suggests momentum has been building around orders like the US$14 million FOX XP deal and shifting expectations about Aehr’s role in AI focused semiconductor testing.

If this AI test equipment story has your attention, it could be a useful time to see what else is moving in the theme with 35 AI infrastructure stocks as a starting list of ideas.

With the shares around US$35.67, trading at only a small discount to the latest analyst price target and reflecting a mix of strong recent returns alongside current losses, investors may need to consider whether there is meaningful upside remaining or if the market is already pricing in future growth.

Preferred Price-to-Sales of 20.5x: Is it justified?

Aehr Test Systems currently trades on a P/S of 20.5x, which looks rich when you set it against both the broader US semiconductor space and closer peers.

The P/S multiple compares the company’s market value to its revenue and is often used for businesses that are not generating profits. In Aehr’s case, the company reported revenue of $53.249m and a net loss of $8.856m, so investors are effectively paying a high price for each dollar of sales while the business remains unprofitable.

Compared with the US semiconductor industry average P/S of 5.8x, Aehr’s 20.5x stands at more than three times that level. Against its peer group average of 3.1x, the gap is even wider. The estimated fair P/S ratio of 7.3x is also materially below the current multiple, which points to a level the market could move toward if sentiment or growth expectations change.

Result: Price-to-Sales of 20.5x (OVERVALUED)

However, you also have to weigh risks such as Aehr’s ongoing net loss of US$8.856m and the potential impact if large AI related equipment orders slow or get delayed.

Next Steps

Feeling mixed after all this, with both strong expectations and clear risks in play? Act quickly, review the numbers for yourself, then weigh up 1 key reward and 2 important warning signs in context before deciding what it all means for you.

Looking for more investment ideas?

If Aehr has sparked your interest, do not stop here. Broaden your watchlist with other clear, data backed ideas that could sharpen your overall portfolio decisions.

• Target stability first by reviewing companies in our 68 resilient stocks with low risk scores that score well on business resilience and lower risk profiles.
• Hunt for quality at a sensible price with the 48 high quality undervalued stocks, focused on companies where fundamentals and valuation screens line up.
• Add potential future standouts to your radar through the screener containing 26 high quality undiscovered gems, highlighting lesser known names with solid underlying numbers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.